news.ucsb.edu10d
‘Brave and bold’ new strategies for cancer immunotherapy
Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...
Frontiers1d
Advancements in Solid Tumor Immunotherapy: Enhancing Efficacy and Overcoming Resistance
In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint ...
Nasdaq5d
Pyxis Oncology Initiates Phase 1/2 Trial for PYX-201 in Combination with KEYTRUDA® for Advanced Solid Tumors
a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic ...
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
Morningstar5d
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic ...